drugset / Trial / NCT07399067
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).
Timeline
- Start
- 2026-02-06
- Primary completion
- 2027-03-23
- Completion
- 2027-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | IBI3002 | Unknown | — | Subcutaneous |